Atezolizumab in Early Stage Non-Small Cell Lung Cancer

Summary

This study focuses on individuals who have inoperable, early stage non-small cell lung cancer. The purpose of the study is to compare the usual treatment alone to using an immunotherapy drug called atezolizumab plus the usual treatment. The usual approach for patients who are not in a study is treatment with radiation alone. Researchers aim to determine whether patients’ lives can be extended by adding the immunotherapy drug atezolizumab to the usual radiation treatment. Participants will be randomly assigned to 1 of 2 groups. The first group will receive atezolizumab plus the usual radiation treatment, and the second group will receive the usual radiation treatment. The use of atezolizumab in this study is investigational.


Inclusion Criteria

  • Patient must have histologically or cytologically proven stage I-IIA or limited T3N0M0 non-small cell lung cancer (NSCLC), without radiographic evidence of nodal or distant involvement (N0M0). Patient may have T3 disease with the exclusion of pericardial involvement. Patients with multifocal tumors with no more than two lesions confirmed or suspected to be synchronous early stage NSCLCs are eligible provided at least one lesion is histologically or cytologically proven to be NSCLC and meets one or more high-risk features
  • Disease must have one or more of the following high-risk features:
Show more

Study Location(s)

  • Cedars-Sinai Cancer at Beverly Hills (THO)
  • Cedars-Sinai Cancer at SOCC


More about this Clinical Trial

Full Title

S1914: A Randomized Phase III Trial of Induction/Consolidation Atezolizumab + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC

Details
Disease Type/Condition

Lung

Principal Investigator

Mirhadi, Amin

Co-Investigators

Behrooz Hakimian, David Hoffman, Jeremy Lorber, Karen Reckamp, Katelyn Atkins, Kevin Scher, Ronald Natale, Sepehr Rokhsar, Sukhmani Padda

Age Group

Adult

Phase

III

IRB Number

STUDY00001762

ClinicalTrials.gov ID

NCT04214262

Key Eligibility
ClinicalTrials.gov

Contact
Email
cancer.trial.info@cshs.org
Want to join the study or
learn more?

Details
Disease Type/Condition

Lung

Principal Investigator

Mirhadi, Amin

Age Group

Adult

Phase

III

IRB Number

S1914

ClinicalTrials.gov ID

NCT04214262

Key Eligibility
ClinicalTrials.gov

Contact
Email
cancer.trial.info@cshs.org
Want to join the study or
learn more?